Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

BACKGROUND: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Care (Basel)
Autors principals: Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia Valeria, Artale, Salvatore, Blasi, Livio, De Laurentiis, Michelino, Atzori, Francesco, Turletti, Anna, Porpiglia, Mauro, Santini, Daniele, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Giordano, Monica, Donadio, Michela, Biganzoli, Laura, Del Mastro, Lucia, Bisagni, Giancarlo, Livi, Lorenzo, Natoli, Clara, Montemurro, Filippo, Riccardi, Ferdinando, Romagnoli, Emanuela, Marchetti, Paolo, Torri, Valter, Pronzato, Paolo, Mustacchi, Giorgio
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098305/
https://ncbi.nlm.nih.gov/pubmed/32231495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000495469
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars